Adherence to Treatment With Artemether-Lumefantrine for Uncomplicated Malaria in Rural Malawi | Zendy

Kimberly E. Mace | Zendy; Dyson Mwandama | Zendy; James Jafali | Zendy; M. Luka | Zendy; Scott Filler | Zendy; J. Sande | Zendy; D. Ali | Zendy; S. Patrick Kachur | Zendy; Don P. Mathanga | Zendy; Jacek Skarbinski | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adherence to Treatment With Artemether-Lumefantrine for Uncomplicated Malaria in Rural Malawi

Author(s) -

Kimberly E. Mace,

Dyson Mwandama,

James Jafali,

M. Luka,

Scott Filler,

J. Sande,

D. Ali,

S. Patrick Kachur,

Don P. Mathanga,

Jacek Skarbinski

Publication year - 2011

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/cir498

Subject(s) - medicine , artemether/lumefantrine , lumefantrine , malaria , sulfadoxine/pyrimethamine , regimen , sulfadoxine , odds ratio , logistic regression , pill , artemether , pediatrics , dosing , pyrimethamine , plasmodium falciparum , artemisinin , pharmacology , immunology

In 2007, Malawi replaced the first-line medication for uncomplicated malaria, sulfadoxine-pyrimethamine-a single-dose regimen-with artemether-lumefantrine (AL)-a 6-dose, 3-day regimen. Because of concerns about the complex dosing schedule, we assessed patient adherence to AL 2 years after routine implementation.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research